Bristol-Myers Squibb licenses potential Alzheimer's drug to Biogen
Biogen has entered into a licensing agreement for BMS-986168 with Bristol-Myers Squibb to initiate Phase II studies for the antibody treatment for Alzheimer’s disease and progressive supranuclear palsy. Read More »
Alerts Sign-up